Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND
NeOnc received Investigational New Drug authorization from the Abu Dhabi Department of Health for NEO212, establishing 610 mg as the recommended Phase 2 dose following the completion of a Phase 1 dose-escalation study. The company's NEO100 program has achieved full enrollment in a Phase 2a study for recurrent IDH1-mutant high-grade glioma, with prior data indicating approximately 24% tumor remission in recurrent glioblastoma patients.
Key figures
- Drug Name
- NEO212
- Phase Of Trial
- Phase 1 (completed), Phase 2a (enrollment full for NEO100)
- Neo212 rp2d mg
- 610
- Credit line usd
- 10000000
- Atm facility usd
- 75000000
- Neo100 remission rate
- 24%
- Insider buying recent usd
- 500000
- Insider buying total ytd usd
- 1000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.